文献速递糖尿病骨质疏松与钙磷/甲状旁腺

F2-异前列腺素与2型糖尿病骨折风险增加相关

F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在Health, Aging, and Body Composition研究的观察性队列中,基线血浆F2-异前列腺素每升高1个SD(对数转换),2型糖尿病组临床骨折风险增加93%(HR=1.93,95%CI 1.26-2.9,P=.002),非糖尿病组无此关联(HR=0.98,95%CI 0.81-1.18,P=.79,交互P<.001)。该关联独立于基线骨密度。

要点

  • 2型糖尿病组对数血浆F2-异前列腺素每升高1个SD,临床骨折风险增加93%(HR=1.93)。
  • 非糖尿病组无关联(HR=0.98),交互作用P<.001。
  • 对数血浆F2-异前列腺素与2型糖尿病组全髋骨密度下降及4年全髋骨密度降低呈中等相关。

核心结论

  • 糖尿病患者血浆F2-异前列腺素水平与临床骨折风险增加相关,且独立于基线骨密度。

研究设计与样本

  • 观察性队列研究,样本来自Health, Aging, and Body Composition研究队列的3075名个体。
  • 纳入基线有血浆F2-异前列腺素测量的老年黑人和白人可走动成人(基线年龄70-79岁),其中2型糖尿病组132例,非糖尿病组571例。

主要发现

  • 多变量调整(包括骨密度、药物和其他危险因素)的Cox比例风险模型显示,2型糖尿病组对数血浆F2-异前列腺素每升高1个SD,临床骨折风险增加93%(HR=1.93,95%CI 1.26-2.9,P=.002)。
  • 非糖尿病组无关联证据(HR=0.98,95%CI 0.81-1.18,P=.79),交互作用P<.001。
  • 2型糖尿病组对数血浆F2-异前列腺素与基线全髋骨密度下降呈中等相关(r=-0.25,P=.003),与4年全髋骨密度降低也呈中等相关(r=-0.28,P=.008)。
  • 两组中对数血浆F2-异前列腺素与循环糖氧化标志物或骨转换标志物均无相关证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Fracture risk is higher in type 2 diabetes (T2D) for a given bone mineral density (BMD) level. Increased oxidative stress in T2D induces diabetic complications and may affect T2D bone fragility. OBJECTIVE: To investigate whether the levels of plasma F2-isoprostanes, a reliable oxidative stress marker, are associated with incident clinical fracture risk in older adults with diabetes. METHODS: An observational cohort study was conducted in a well-characterized cohort from Health, Aging, and Body Composition study. PARTICIPANTS: Older Black and White ambulatory adults with baseline plasma F2-isoprostanes measurements (baseline age 70-79 years, T2D: N = 132; nondiabetes: N = 571) were selected from the study cohort of 3075 individuals. Risk of incident clinical fractures was assessed. RESULTS: In the Cox proportional hazard model with multivariate adjustments (including BMD, medications, and other risk factors), a 93% increase in incident clinical fracture risk was significantly associated with each SD increase in log plasma F2-isoprostanes in the T2D group (hazard ratio [HR] = 1.93 [95% CI, 1.26-2.9] P = .002), but there was no evidence of an association in the nondiabetes group (HR = 0.98 [95% CI 0.81-1.18] P = .79, P for interaction <.001). Log plasma F2-isoprostanes were moderately correlated with a decline in baseline total hip BMD (r = -0.25, P = .003), and with a 4-year decrease in total hip BMD (r = -0.28, P = .008) in T2D. There was no evidence of correlation between log plasma F2-isoprostanes and circulating glycoxidation markers or bone turnover markers in either group. CONCLUSION: Plasma F2-isoprostanes levels in individuals with diabetes are associated with increased incident clinical fracture risk independently of baseline BMD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang B, Dhaliwal R, Ewing SK, et al. F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39512199. doi:10.1210/clinem/dgae788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。